Summary
1.01 -0.01(-0.98%)09/06/2024
Adial Pharmaceuticals Inc (ADIL)
Adial Pharmaceuticals Inc (ADIL)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.98 | 2.96 | 0.01 | -18.88 | -52.58 | -73.97 | -37.27 | -75.06 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.01 | |
| Open | 1.01 | |
| High | 1.04 | |
| Low | 0.98 | |
| Volume | 74,089 | |
| Change | -0.01 | |
| Change % | -0.98 | |
| Avg Volume (20 Days) | 139,461 | |
| Volume/Avg Volume (20 Days) Ratio | 0.53 | |
| 52 Week Range | 0.77 - 4.36 | |
| Price vs 52 Week High | -76.83% | |
| Price vs 52 Week Low | 31.17% | |
| Range | 0.00 | |
| Gap Up/Down | -0.03 | |
Fundamentals | ||
| Market Capitalization (Mln) | 6 | |
| EBIDTA | -9,313,408 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 10.67 | |
| Book Value | 0.3520 | |
| Earnings Per Share | -1.0040 | |
| EPS Estimate Current Quarter | -0.2200 | |
| EPS Estimate Next Quarter | -0.2100 | |
| EPS Estimate Current Year | -0.9700 | |
| EPS Estimate Next Year | -0.7200 | |
| Diluted EPS (TTM) | -1.0040 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -1.1230 | |
| Return on equity (TTM) | -2.3887 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 7.9316 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 20,766,700 | |
| Shares Float | 17,247,793 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 19.23 | |
| Institutions (%) | 9.41 | |
09/04 09:00 EST - globenewswire.com
Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GLEN ALLEN, Va., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial Pharmaceuticals, will be participating in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.
Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GLEN ALLEN, Va., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial Pharmaceuticals, will be participating in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.
08/14 08:30 EST - globenewswire.com
Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
GLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2024.
Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
GLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2024.
08/07 09:00 EST - globenewswire.com
Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04 Topline results expected during the fourth quarter GLEN ALLEN, Va., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced that the final patient has completed the last dose in the pharmacokinetics study of AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day).
Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04 Topline results expected during the fourth quarter GLEN ALLEN, Va., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced that the final patient has completed the last dose in the pharmacokinetics study of AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day).
07/31 08:30 EST - globenewswire.com
Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044
Expected New Patent Based on Extensive Review of Data and Information Expected New Patent Based on Extensive Review of Data and Information
Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044
Expected New Patent Based on Extensive Review of Data and Information Expected New Patent Based on Extensive Review of Data and Information
07/23 12:00 EST - investorplace.com
Why Is Adial Pharmaceuticals (ADIL) Up 61% Today?
Adial Pharmaceuticals (NASDAQ:ADIL) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company announced an update on its AD04 study. Adial Pharmaceuticals notes that AD04 is progressing to a second cohort in its pharmacokinetics study.
Why Is Adial Pharmaceuticals (ADIL) Up 61% Today?
Adial Pharmaceuticals (NASDAQ:ADIL) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company announced an update on its AD04 study. Adial Pharmaceuticals notes that AD04 is progressing to a second cohort in its pharmacokinetics study.
07/23 08:30 EST - globenewswire.com
Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Patient dosing in the second cohort has commenced following the successful completion of the first cohort Patient dosing in the second cohort has commenced following the successful completion of the first cohort
Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Patient dosing in the second cohort has commenced following the successful completion of the first cohort Patient dosing in the second cohort has commenced following the successful completion of the first cohort
06/20 08:30 EST - globenewswire.com
Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder
AD04 reduced heavy drinking days among heavy drinking individuals with alcohol use disorder and a specific genetic profile, as identified by a companion diagnostic test (CDx) AD04 reduced heavy drinking days among heavy drinking individuals with alcohol use disorder and a specific genetic profile, as identified by a companion diagnostic test (CDx)
Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder
AD04 reduced heavy drinking days among heavy drinking individuals with alcohol use disorder and a specific genetic profile, as identified by a companion diagnostic test (CDx) AD04 reduced heavy drinking days among heavy drinking individuals with alcohol use disorder and a specific genetic profile, as identified by a companion diagnostic test (CDx)
06/05 15:17 EST - investorplace.com
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
Making millions through the stock market is only possible in a few ways. Investors need one of these three things: Massive sums of capital to begin with Decades of time and more modest sums of capital More modest sums of capital and a combination of risk and luck We will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025.
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
Making millions through the stock market is only possible in a few ways. Investors need one of these three things: Massive sums of capital to begin with Decades of time and more modest sums of capital More modest sums of capital and a combination of risk and luck We will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025.
05/29 08:30 EST - globenewswire.com
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City.
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City.
05/15 08:30 EST - globenewswire.com
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2024.
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2024.
04/22 08:30 EST - globenewswire.com
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office. This patent expands Adial's intellectual property protection and covers the combination of the Company's proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and other drug dependencies, such as opioid use disorder (OUD), with the Company's lead investigational new drug product AD04.
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office. This patent expands Adial's intellectual property protection and covers the combination of the Company's proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and other drug dependencies, such as opioid use disorder (OUD), with the Company's lead investigational new drug product AD04.
04/10 14:15 EST - invezz.com
Adial Pharmaceuticals posts promising update on alcohol disorder drug
Adial Pharmaceuticals Inc (NASDAQ: ADIL) is up 60% today following a promising update on its alcohol disorder drug. What it means for Adial Pharmaceuticals stock The $7.7 million company based out of Virginia, United States said its AD04 did well in a clinical trial of Alcohol Use Disorder (AUD) patients.
Adial Pharmaceuticals posts promising update on alcohol disorder drug
Adial Pharmaceuticals Inc (NASDAQ: ADIL) is up 60% today following a promising update on its alcohol disorder drug. What it means for Adial Pharmaceuticals stock The $7.7 million company based out of Virginia, United States said its AD04 did well in a clinical trial of Alcohol Use Disorder (AUD) patients.
04/10 11:53 EST - investorplace.com
Why Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today?
Adial Pharmaceuticals (NASDAQ: ADIL ) stock is heading higher on Wednesday following positive results from a peer review of its Alcohol Use Disorder ( AUD ) treatment. This peer review focuses on Phase 3 clinical trial results for AD04.
Why Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today?
Adial Pharmaceuticals (NASDAQ: ADIL ) stock is heading higher on Wednesday following positive results from a peer review of its Alcohol Use Disorder ( AUD ) treatment. This peer review focuses on Phase 3 clinical trial results for AD04.
04/10 08:30 EST - globenewswire.com
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trial Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trial
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trial Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trial
04/02 08:30 EST - globenewswire.com
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year-End 2023 GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023.
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year-End 2023 GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023.
03/01 19:00 EST - globenewswire.com
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,150,000 shares of common stock of the Company originally issued in October 2023, having an exercise price of $2.82 per share and eighteen months term. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-275397). The gross proceeds to the Company from the exercise of the warrants are expected to be $3,530,500, prior to deducting placement agent fees and estimated offering expenses.
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,150,000 shares of common stock of the Company originally issued in October 2023, having an exercise price of $2.82 per share and eighteen months term. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-275397). The gross proceeds to the Company from the exercise of the warrants are expected to be $3,530,500, prior to deducting placement agent fees and estimated offering expenses.
02/28 09:30 EST - globenewswire.com
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
New patent strengthens Adial's patent portfolio and covers AD04's unique ability to target the serotonin transporter gene for the potential treatment of opioid use disorder New patent strengthens Adial's patent portfolio and covers AD04's unique ability to target the serotonin transporter gene for the potential treatment of opioid use disorder
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
New patent strengthens Adial's patent portfolio and covers AD04's unique ability to target the serotonin transporter gene for the potential treatment of opioid use disorder New patent strengthens Adial's patent portfolio and covers AD04's unique ability to target the serotonin transporter gene for the potential treatment of opioid use disorder
02/15 09:00 EST - accesswire.com
Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20
CHARLOTTESVILLE, VA / ACCESSWIRE / February 15, 2024 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Winter Wrap-Up MicroCap Rodeo Conference, which will be held virtually Tuesday, February 20 through Friday, February 23, 2024. Cary Claiborne, Chief Executive Officer of Adial, is scheduled to present on Tuesday, February 20 at 11:30 a.m.
Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20
CHARLOTTESVILLE, VA / ACCESSWIRE / February 15, 2024 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Winter Wrap-Up MicroCap Rodeo Conference, which will be held virtually Tuesday, February 20 through Friday, February 23, 2024. Cary Claiborne, Chief Executive Officer of Adial, is scheduled to present on Tuesday, February 20 at 11:30 a.m.
02/13 09:15 EST - globenewswire.com
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
Expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence Expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
Expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence Expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence